Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 38 clinical trials
  • 0 views
  • 29 Dec, 2021
  • 1 location
ARNI in Asymptomatic Patients With Elevated Natriuretic Peptide and Elevated Left Atrial Volume Index eLEvation

The purpose of this study is to determine whether LCZ696 (valsartan/sacubitril) is safe and has beneficial effects on the heart and blood vessels in patients with high blood pressure and/or diabetes or other risk factors for developing heart failure (elevated levels of natriuretic peptide and elevated left atrial volume index). …

valsartan
diabetes
natriuretic peptide
heart failure
sacubitril
  • 6 views
  • 08 Nov, 2020
  • 1 location
Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Left Ventricular Systolic Dysfunction.

(SCD). At present our tools to reliably risk stratify these patients with mild-moderate systolic dysfunction (LVEF 36-50%) are poor. It is likely that these patients have ventricular scar and/or

systolic dysfunction
beta-adrenergic blocking agents
left ventricular systolic dysfunction
ace inhibitor
cardiomyopathy
  • 84 views
  • 26 Jan, 2021
  • 20 locations
A Multicenter Study to Evaluate Long-term Safety and Tolerability of Open Label Sacubitril/Valsartan in Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed Study CLCZ696B2319

The purpose of this study is to evaluate long-term safety and tolerability data in eligible CLCZ696B2319 (PANORAMA-HF) patients receiving open-label sacubitril/valsartan.

valsartan
  • 73 views
  • 19 Sep, 2022
  • 23 locations
Long-term Beta-blocker Therapy After Acute Myocardial Infarction (SMART-DECISION)

(HF) or left ventricular systolic dysfunction after acute myocardial infarction (AMI). Prospective, open-label, randomized, multicenter, noninferiority trial to determine

myocardial infarction
heart failure
infarct
beta blockers
acute myocardial infarction
  • 0 views
  • 25 May, 2022
  • 1 location
Effects of Carvedilol on Cardiotoxicity in Cancer Patients Submitted to Anthracycline Therapy

systolic dysfunction in cancer patients obtained with anthracycline chemotherapy, in different schedules and doses.

treatment regimen
anthracyclines
primary cancer
  • 0 views
  • 08 Oct, 2021
  • 1 location
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, …

adult acute myelogenous leukemia
cancer
cytarabine
anthracyclines
cytarabine/daunorubicin
  • 141 views
  • 10 May, 2022
  • 98 locations
Conduction System Pacing vs Biventricular Resynchronization Therapy in Systolic Dysfunction and Wide QRS: CONSYST-CRT. (CONSYST-CRT)

Conduction system pacing vs biventricular resynchronization therapy in systolic dysfunction and wide QRS (CONSYST-CRT randomized clinical trial) is a non-inferiority trial that aims to study the

  • 0 views
  • 24 Mar, 2022
Aerobic Exercise is Cardio-protective in Hemato-oncological Disease and New-onset Chemotherapy (AEROHEMONCO)

systolic dysfunction and symptomatic HF is mainly based on the indication of inhibitors of the angiotensin-converting enzyme and beta-blockers among other pharmaceutical and no pharmaceutical interventions

  • 0 views
  • 04 Oct, 2022
  • 1 location
Prevention of Age-associated Cardiac and Vascular Dysfunction Through Nrf2 Signaling Using the Nutritional Supplement Sulforaphane (CardiacAging)

Our local IRB approved clinical studies seeking proof of principle for the hypothesis that SFN can be safely administered to humans at doses sufficient to protect age-associated cardiac dysfunctions. Beneficial effects of SFN-therapy will be assessed by Pre- and post-intervention echocardiography, and exercise endurance at 0 and 24 weeks. Peripheral …

Accepts healthy volunteers
  • 0 views
  • 20 Sep, 2022